Shoulder Innovations closed a $40 million Series E equity financing round. Proceeds will be used primarily to advance commercialization of InSet Total Shoulder and Reverse Shoulder Arthroplasty Systems and support new product development, as well as for general corporate purposes.
InSet technology has been shown in testing to significantly reduce glenoid implant micro-motion and simplify the surgical technique, potentially reducing complications or increasing implant longevity.
“Over recent years, we have significantly expanded our product line, strengthened our sales organization, and emerged as a pure-play leader in shoulder arthroplasty,” said Rob Ball, CEO of Shoulder Innovations. “We appreciate the support of our new and existing investors and see this financing as well-timed as we hone our focus on accelerating commercial momentum and advance our mission of enabling best-in-class outcomes for shoulder specialists and their patients.”
Shoulder Innovations closed a $40 million Series E equity financing round. Proceeds will be used primarily to advance commercialization of InSet Total Shoulder and Reverse Shoulder Arthroplasty Systems and support new product development, as well as for general corporate purposes.
InSet technology has been shown in testing to significantly...
Shoulder Innovations closed a $40 million Series E equity financing round. Proceeds will be used primarily to advance commercialization of InSet Total Shoulder and Reverse Shoulder Arthroplasty Systems and support new product development, as well as for general corporate purposes.
InSet technology has been shown in testing to significantly reduce glenoid implant micro-motion and simplify the surgical technique, potentially reducing complications or increasing implant longevity.
“Over recent years, we have significantly expanded our product line, strengthened our sales organization, and emerged as a pure-play leader in shoulder arthroplasty,” said Rob Ball, CEO of Shoulder Innovations. “We appreciate the support of our new and existing investors and see this financing as well-timed as we hone our focus on accelerating commercial momentum and advance our mission of enabling best-in-class outcomes for shoulder specialists and their patients.”
Copy to clipboard 
